Johnson & Johnson Says Darzalex Regimens Show Meaningful Responses In Patients With Multiple Myeloma
Data from the Phase 3 AURIGA study show Darzalex Faspro plus lenalidomide maintenance therapy following autologous stem cell transplant (ASCT) significantly increases MRD-negative conversion rates at ...
J&J releases encouraging data on Talvey combination therapies
Johnson & Johnson reports positive results for Talvey in combination with Darzalex Faspro, pomalidomide and Tecvayli in the ...
The American Journal of Managed Care9h
CEPHEUS: Sub-Q Daratumumab With VRd Improves MRD Negativity, PFS in Myeloma if Transplant Deferred
The trial is seen as a complement to the MAIA trial, which had shown a significant overall survival benefit with daratumumab ...
The American Journal of Managed Care11h
Talquetamab Combo Updates Show Durable Responses in Heavily Pretreated Patients
An oral session Friday at the International Myeloma Society 21st Annual Meeting & Exposition offered updates for the TRIMM-2 ...